SGEN - シアトル・ジェネティクス （Seattle Genetics Inc.）

Seagen (SGEN) rose 1.2% ahead of a Monday deadline for an antitrust initial review of its planned $43 billion sale to Pfizer (PFE)

Seagen (NASDAQ: SGEN ) has outperformed the market over the past 10 years by 9.17% on an annualized basis producing an average annual return of 19.29%. Currently, Seagen has a market capitalization of $36.75 billion. Buying $1000 In SGEN: If an … Full story available on Benzinga.com

Pfizer is set to acquire Seagen for $43 billion, with the deal expected to close later this year or in early 2024, subject to regulatory approvals. Click here for a detailed analysis.

When investors hear the words “undervalued biotech stocks to buy,” they frequently think of companies in the clinical trial stage. That’s understandable. If you can buy a company’s stock before it releases a game-changing drug or therapeutic into the market, you can make a fortune. That line of thinking was displayed in 2020 when many biotech companies raced to produce a Covid-19 vaccine. But every investor also knows that many of those moonshots never pan out. That’s not the kind of uncertainty you need in this current market. A better option is to look at the companies that already have FDA-approved drugs in the market and a pipeline of potential products on the way. This increases your chance of success. And the good news is that there are several high-potential biotech stocks . By this, I mean the stocks are trading below the average price-to-earnings of the biotech sector, which is around 19x as of this writing. These stocks also have other catalysts that make them compelling stocks to buy.

WASHINGTON (dpa-AFX) - The biotechnology company Seagen Inc. (SGEN) announced on Tuesday that its stockholders have approved a proposal under which Pfizer will acquire Seagen.Under the merger agre…

According to Benzinga Pro data, during Q2, Seattle Genetics (NASDAQ: SGEN ) posted sales of $497.50 million. Earnings were up 1.22%, but Seattle Genetics still reported an overall loss of $134.83 million. Seattle Genetics collected $426.46 million in revenue during Q1, but reported earnings showed a $136.49 million loss. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a … Full story available on Benzinga.com

Investors have focused on rumors of a Merck acquisition of Seagen. Read why I would wait on SGEN stock and re-evaluate if the deal doesn''t happen.

Seagen’s innovative technology for delivering chemotherapy is blossoming.

https://www.investing.com/news/pro/seagen-receives-investment-bank-analyst-rating-update-432SI-2859855

Related Stocks: SGEN , VRTX , MCK , MDT , ISRG ,

Investors have focused on rumors of a Merck acquisition of Seagen. Read why I would wait on SGEN stock and re-evaluate if the deal doesn''t happen.

Seagen’s innovative technology for delivering chemotherapy is blossoming.

https://www.investing.com/news/pro/seagen-receives-investment-bank-analyst-rating-update-432SI-2859855

Related Stocks: SGEN , VRTX , MCK , MDT , ISRG ,

Seagen Inc (NASDAQ: SGEN ) released its Q2 earnings and kept quiet on any update on the M&A front as rumors fly around a potential Merck & Co Inc (NYSE: MRK ) buyout. Related: Merck''s Potential Buyout Of Seagen Expected Within Next Few Weeks: Report . Seagen reported Q2 sales of $497.5 million, up 28% Y/Y, … Full story available on Benzinga.com